上海齐鲁锐格医药研发有限公司 Shanghai Qiluruge Pharmaceutical Research And Development Co. Ltd
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity 2024-03-08 23:24
Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy 2023-12-08 07:39
Regor Therapeutics Announces Completion of $90 Million Series B Financing 2021-02-19 08:00
1